FDA wants investigation into Avandia conflict: report
NEW YORK (Reuters) - The U.S. Food and Drug Administration has asked the Department of Health and Human Services to investigate whether one of the panelists at a recent safety meeting on the GlaxoSmithKline PLC drug Avandia had a conflict of interest, according to a report by the Wall Street Journal.
David Capuzzi, an endocrinologist in Philadelphia, has received $14,000 from Glaxo for speaking on behalf of another drug, Lovaza, according to the newspaper report.
Capuzzi said he told the FDA about his connection to Glaxo and the FDA said it had vetted all members of its advisory panel for conflicts, the newspaper reported.
- Tweet this
- Share this
- Digg this
- Boxer Sarita Devi faces action after refusing medal at Asian Games
- Boxer Sarita Devi showed lack of sportsmanship, say organisers
- UPDATE 8-Dallas Ebola patient vomited outside apartment on way to hospital
- Appointment of Arvind Subramanian as chief economic adviser hits Modi hurdle
- Amazon to sell packaged food and beverages in India - Economic Times
India could run out of a critical medicine in its free HIV/AIDS drugs programme in three weeks due to bureaucratic bungling, a senior government official said, leaving more than 150,000 sufferers without life-saving drugs for about a month. Full Article